Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus docetaxel and cisplatin in recurrent or metastatic oral squamous cell carcinoma
NCT05611463Phase 2Unknown
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- Jun 2020
- Primary completion
- Dec 2022
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in oral squamous cell carcinoma (OSCC), sponsored by Shanghai Ninth People's Hospital. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
oral squamous cell carcinoma (OSCC)
Beyond the preview
Go deeper on NCT05611463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05611463.